Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1259-1273

  Gong, Jingjing ^a   Xie, Jianping ^a   Bedolla, Roble ^a   Rivas, Paul ^a   Chakravarthy, Divya ^a   Freeman, James W ^a   Reddick, Robert ^b   Kopetz, Scott ^c   Peterson, Amanda ^b   Wang, Huamin ^c   Fischer, Susan M ^d   Kumar, Addanki P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; E PROSTANOID 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL PRODUCT; NEXRUTINE; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROSTAGLANDIN RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FIBROSIS; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VIVO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; NF-KAPPA B; PANCREATIC NEOPLASMS; PLANT EXTRACTS; PROTEIN BINDING; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895815843     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1664     Document Type: Article

References (47)

1. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013;144:1316-26.
2. Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg 2012;255:95.
3. Guo Y, Xu X, Qi W, Xie C, Wang G, Zhang A, et al. Synergistic antitumor interactions between gemcitabine and clofarabine. Mol Med Rep 2012;5:734-8.
4. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491:399-405.
5. Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, et al. Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 2012;11:2127-37.
6. Steele CW, Jamieson NB, Evans TR, McKay CJ, Sansom OJ, Morton JP, et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 2013;108:997-1003.
7. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 2012;9:454-67.
8. Garcia GE, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP. Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia 2006;8: 523-33.
9. Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, et al. Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 2007;13: 2784-94.
10. Habbe N, Shi G, Meguid RA, Fendrich V, Esni F, Chen H, et al. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A 2008;105:18913-8.
11. Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM. Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest 2005;85:1003-12.
12. Ganapathy M, Ghosh R, Jianping X, Zhang X, Bedolla R, Schoolfield J, et al. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 2009;15:1601-11.
13. Colby JKL, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, et al. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia (New York, NY) 2008;10:782.
14. Surh YJ, Bode AM, Dong Z. Breaking the NF-kappaB and STAT3 alliance inhibits inflammation and pancreatic tumorigenesis. Cancer Prev Res (Phila) 2010;3:1379-81.
15. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003;125:891-905.
16. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, et al. Function of nuclear factor kB in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
17. He G, Karin M. NF-kB and STAT3-key players in liver inflammation and cancer. Cell Res 2011;21:159-68.
18. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-9.
19. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-24.
20. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-46.
21. Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S, Beger HG. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002;25:26-30.
22. Kirtikara K, Morham SG, Raghow R, Laulederkind SJ, Kanekura T, Goorha S, et al. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med 1998;187: 517-23.
23. Hasan S, Satake M, Dawson DW, Funahashi H, Angst E, Go VL, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 2008;37:121-7.
24. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004;3:1031-9.
25. Breyer MD, Breyer RM. Prostaglandin E receptors and the kidney.AmJ Physiol Renal Physiol 2000;279:F12-23.
26. Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci U S A 1998;95:15792-7.
27. Kamiyama M, Pozzi A, Yang L, DeBusk L, Breyer R, Lin P. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006;25: 7019-28.
28. Charo C, Holla V, Arumugam T, Hwang R, Yang P, Dubois RN, et al. Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas 2013;42:467-74.
29. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49.
30. Reid-Lombardo KM, Fridley BL, Bamlet WR, Cunningham JM, Sarr MG, Petersen GM. Inflammation-related gene variants as risk factors for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011;20: 1251-4.
31. Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Activation of JAK-STAT pathway is required for platelet-derived growth factorinduced proliferation of pancreatic stellate cells. World J Gastroenterol 2005;11:3385-91.
32. Aoki H, Ohnishi H, Hama K, Shinozaki S, Kita H, Osawa H, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines.AmJ Physiol Cell Physiol 2007; 292:C259-68.
33. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Hamada S, et al. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 2009;58:550-9.
34. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 2013;1830:3670-95.
35. Kumar AP, Graham H, Robson C, Thompson IM, Ghosh R. Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management. Mini Rev Med Chem 2010; 10:388-97.
36. Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simoes M, et al. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A 2012;109:E2361-70.
37. Lee H, Deng J, Xin H, Liu Y, Pardoll D, Yu H. A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-kappaB in tumors. Cancer Res 2011;71:3772-80.
38. McFarland BC, Gray GK, Nozell SE, Hong SW, Benveniste EN. Activation of the NF-kB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res 2013;11:494-505.
39. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319-29.
40. Nakagawa N, Yuhki K, Kawabe J, Fujino T, Takahata O, Kabara M, et al. The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 2012;82:158-71.
41. Huang SK, White ES, Wettlaufer SH, Grifka H, Hogaboam CM, Thannickal VJ, et al. Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J 2009;23:4317-26.
42. Wu J, Zhang Y, Frilot N, Kim JI, Kim WJ, Daaka Y. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem 2011;286: 33954-62.
43. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002;109: 883-93.
44. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kB-regulated gene products. Cancer Res 2007;67:3853-61.
45. Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, et al. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res 2007;138:163-9.
46. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, et al. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 2011;71:5182-93.
47. Zhang R, Humphreys I, Sahu RP, Shi Y, Srivastava SK. In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis 2008;13:1465-78.